


Amendments to the Claims

Please amend the claims as follows:

Claims 1-14 (Cancelled)

Claim 15 (Currently Amended) A compound medicament according to ~~any of~~
~~Claims 1 to 12~~ formula (I)



wherein:

n is 1, 2, 3 or 4;

R¹ is selected from

- (a) an optionally substituted straight chain or branched chain C₁₋₆ alkyl group,
- (b) an optionally substituted straight chain or branched chain C₂₋₆ alkenyl group,
- (c) an optionally substituted straight chain or branched chain C₂₋₆ alkynyl group,
- (d) Aryl,
- (e) Aromatic heterocycle,
- (f) Heterocycle, and
- (g) hydrogen;

where the optional substituents in groups (a), (b) and (c) above are selected

from: C₃₋₇ cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR⁹, NR⁹R¹⁰,

S(O)_pR⁹, OC(O)R¹⁰, CO₂R⁹, CONR⁹R¹⁰, SO₂NR⁹R¹⁰, halo and NHSO₂R⁹,

and where p is 0, 1 or 2;

R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are each independently selected from hydrogen and

straight chain or branched chain C₁₋₆ alkyl optionally substituted by OR⁹ or halo;

R⁹ and R¹⁰ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R¹¹, halo, OR¹², NR¹²R¹³, NR¹²CO₂R¹¹, CO₂R¹², NR¹²SO₂R¹¹, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹, OC(O)R¹², SO₂NR¹²R¹³ and C(O)NR¹²R¹³, where R¹¹ is straight chain or branched chain C₁₋₆ alkyl and R¹² and R¹³ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl;

Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR¹², NR¹²R¹³, CO₂R¹², NR¹²CO₂R¹¹, R¹¹, halo, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹, OC(O)R¹², NR¹²SO₂R¹¹, SO₂NR¹²R¹³ and C(O)NR¹²R¹³; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR¹², NR¹²R¹³, CO₂R¹², NR¹²CO₂R¹³, R¹¹, halo, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹, OC(O)R¹², NR¹²SO₂R¹¹, SO₂NR¹²R¹³ and C(O)NR¹²R¹³,

or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of said compound or said tautomer ~~for use as a~~ wherein said medicament is for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

Claim 16-21 (Cancelled)